Omeros Corporation (OMER) - Net Assets
Based on the latest financial reports, Omeros Corporation (OMER) has net assets worth $-63.33 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($286.17 Million) and total liabilities ($349.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Omeros Corporation's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-63.33 Million |
| % of Total Assets | -22.13% |
| Annual Growth Rate | N/A |
| 5-Year Change | -609.8% |
| 10-Year Change | N/A |
| Growth Volatility | 163.55 |
Omeros Corporation - Net Assets Trend (2007–2025)
This chart illustrates how Omeros Corporation's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Omeros Corporation to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Omeros Corporation (2007–2025)
The table below shows the annual net assets of Omeros Corporation from 2007 to 2025. For live valuation and market cap data, see OMER stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-121.23 Million | +33.61% |
| 2024-12-31 | $-182.61 Million | -630.93% |
| 2023-12-31 | $-24.98 Million | -129.16% |
| 2022-12-31 | $85.68 Million | +260.32% |
| 2021-12-31 | $23.78 Million | +119.69% |
| 2020-12-31 | $-120.75 Million | -10.76% |
| 2019-12-31 | $-109.02 Million | -208.85% |
| 2018-12-31 | $100.16 Million | +3659.20% |
| 2017-12-31 | $-2.81 Million | +92.49% |
| 2016-12-31 | $-37.45 Million | -42.74% |
| 2015-12-31 | $-26.23 Million | +38.50% |
| 2014-12-31 | $-42.65 Million | -132.02% |
| 2013-12-31 | $-18.38 Million | +91.43% |
| 2012-12-31 | $-214.58 Million | -3763.47% |
| 2011-12-31 | $-5.55 Million | -127.13% |
| 2010-12-31 | $20.47 Million | -52.56% |
| 2009-12-31 | $43.15 Million | +147.33% |
| 2008-12-31 | $-91.17 Million | -30.35% |
| 2007-12-31 | $-69.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Omeros Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 84027500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $716.00K | % |
| Other Components | $791.75 Million | % |
| Total Equity | $-121.23 Million | 100.00% |
Omeros Corporation Competitors by Market Cap
The table below lists competitors of Omeros Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Laan & Spar Bank AS
CO:LASP
|
$697.78 Million |
|
India Glycols Limited
NSE:INDIAGLYCO
|
$697.80 Million |
|
Indika Energy Tbk
JK:INDY
|
$698.12 Million |
|
Dakota Gold Corp.
NYSE MKT:DC
|
$698.29 Million |
|
Logistea AB Series B
ST:LOGI-B
|
$697.64 Million |
|
Elec-Tech International Co Ltd
SHE:002005
|
$697.50 Million |
|
Regional Container Lines Public Company Limited
BK:RCL-R
|
$697.45 Million |
|
RaySearch Laboratories AB (publ)
ST:RAY-B
|
$697.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Omeros Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -182,609,000 to -121,231,000, a change of 61,378,000.
- Net loss of 3,350,000 reduced equity.
- New share issuances of 39,343,000 increased equity.
- Other factors increased equity by 25,385,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.35 Million | -2.76% |
| Share Issuances | $39.34 Million | +32.45% |
| Other Changes | $25.39 Million | +20.94% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Omeros Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $-4.90 | $9.64 | x |
| 2008-12-31 | $-8.48 | $9.64 | x |
| 2009-12-31 | $5.98 | $9.64 | x |
| 2010-12-31 | $0.96 | $9.64 | x |
| 2011-12-31 | $-0.25 | $9.64 | x |
| 2012-12-31 | $-8.88 | $9.64 | x |
| 2013-12-31 | $-0.64 | $9.64 | x |
| 2014-12-31 | $-1.28 | $9.64 | x |
| 2015-12-31 | $-0.70 | $9.64 | x |
| 2016-12-31 | $-0.93 | $9.64 | x |
| 2017-12-31 | $-0.06 | $9.64 | x |
| 2018-12-31 | $13.38 | $9.64 | x |
| 2019-12-31 | $-2.20 | $9.64 | x |
| 2020-12-31 | $-2.11 | $9.64 | x |
| 2021-12-31 | $0.38 | $9.64 | x |
| 2022-12-31 | $1.37 | $9.64 | x |
| 2023-12-31 | $-0.40 | $9.64 | x |
| 2024-12-31 | $-3.14 | $9.64 | x |
| 2025-12-31 | $-1.91 | $9.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Omeros Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-32.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 0.00% | -1200.78% | 0.07x | 0.00x | $-16.10 Million |
| 2008 | 0.00% | -2036.50% | 0.05x | 0.00x | $-14.71 Million |
| 2009 | -48.88% | -1460.46% | 0.02x | 1.44x | $-25.40 Million |
| 2010 | -142.90% | -1389.60% | 0.05x | 2.23x | $-31.30 Million |
| 2011 | 0.00% | -630.99% | 0.17x | 0.00x | $-27.99 Million |
| 2012 | 0.00% | -638.39% | 0.23x | 0.00x | $-16.99 Million |
| 2013 | 0.00% | -2487.25% | 0.10x | 0.00x | $-37.96 Million |
| 2014 | 0.00% | -13668.46% | 0.05x | 0.00x | $-69.41 Million |
| 2015 | 0.00% | -555.90% | 0.28x | 0.00x | $-72.47 Million |
| 2016 | 0.00% | -160.38% | 0.62x | 0.00x | $-63.00 Million |
| 2017 | 0.00% | -82.50% | 0.56x | 0.00x | $-53.20 Million |
| 2018 | -19.50% | -424.39% | 0.31x | 0.15x | $-191.77 Million |
| 2019 | 0.00% | -75.57% | 0.82x | 0.00x | $-73.58 Million |
| 2020 | 0.00% | -187.04% | 0.41x | 0.00x | $-125.99 Million |
| 2021 | -468.52% | -123.08% | 0.22x | 17.63x | $-113.79 Million |
| 2022 | 55.34% | 0.00% | 0.00x | 6.90x | $38.85 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-115.31 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-138.55 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $8.77 Million |
Industry Comparison
This section compares Omeros Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Omeros Corporation (OMER) | $-63.33 Million | 0.00% | N/A | $697.70 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinic… Read more